Table 3.
Clinical features and outcomes of COVID-19 patients with or without a history of CVD.
| Clinical features and outcomes | History of CVD n = 109 | No history of CVD n = 2,445 | P-Value |
|---|---|---|---|
| Time from symptoms to admission, mean ± SD | 23.23 ± 14.59 | 24.07 ± 12.97 | 0.501 |
| Severity on admission (proportion) | <0.001* | ||
| Mild cases | 1 (0.9) | 27 (1.1) | |
| Moderate cases | 55 (50.5) | 1,731 (70.8) | |
| Severe cases | 49 (45.0) | 660 (27.0) | |
| Critical cases | 4 (3.7) | 27 (1.1) | |
| Drug treatment (proportion) | |||
| Antibiotics | 54 (49.5) | 799 (32.7) | <0.001 |
| Antivirals | 48 (44.0) | 1,191 (48.8) | 0.333 |
| Immune support | 53 (48.6) | 801 (32.8) | 0.001 |
| Glucocorticoids | 26 (23.9) | 345 (14.1) | 0.005 |
| Mechanical ventilation (proportion) | 9 (8.3) | 36 (1.5) | <0.001 |
| Non-Invasive | 7 (6.4) | 32 (1.3) | <0.001 |
| Invasive | 5 (4.6) | 12 (0.5) | <0.001 |
| ECMO | 0 | 2 (0.1) | 1.000 |
| ICU care (proportion) | 4 (3.7) | 17 (0.7) | 0.005 |
| Shock (proportion) | 9 (8.3) | 47 (1.9) | <0.001 |
| Length of hospital day, mean±SD | 14.9 (9.9) | 14.7 (8.7) | 0.818 |
| Clinical outcomes (proportion) | |||
| Discharged | 102 (93.6) | 2,407 (98.4) | 0.001 |
| Died | 7 (6.4) | 38 (1.6) | 0.001 |
| Severe events (proportion) | 14 (12.8%) | 63 (2.6%) | <0.001 |
Data are described as mean ± SD or proportion (%); χ2 test, Fisher exact test, T-test was used to calculate P-values when appropriate.